LUNG Pulmonx Corp

Nasdaq Surgical & Medical Instruments & Apparatus DE CIK: 0001127537
AI RATING
SELL
78% Confidence

Investment Thesis

Pulmonx demonstrates excellent gross margins (77.9%) indicating strong product viability, but operates at massive losses with negative operating cash flow (-$10.1M), unsustainable operating margin (-62.9%), and insufficient revenue growth (8% YoY) to offset burn. While the $61.6M cash position provides ~6-year runway, the company has not demonstrated a viable path to profitability and will likely require additional capital raises.

Strengths

  • + Exceptional gross margin of 77.9% demonstrates strong pricing power and product economics
  • + Fortress balance sheet with $61.6M cash (51% of total assets) providing substantial operational runway
  • + Strong liquidity metrics (4.91x current ratio, 4.04x quick ratio) eliminate near-term solvency concerns
  • + Moderate leverage (0.82x debt-to-equity) provides financial flexibility
  • + 8% revenue growth YoY shows incremental market traction despite losses

Risks

  • ! Deeply unprofitable with -$13.7M net income on only $20.6M revenue (-66.3% net margin)
  • ! Negative operating cash flow of -$10.1M annually indicates unsustainable business model at current scale
  • ! Cannot cover interest expense from operations (negative interest coverage ratio of -14.7x)
  • ! Burn rate of ~$10M annually requires external funding within 6 years even with current cash reserves
  • ! Revenue growth of 8% is far below the rate needed to achieve profitability given current cost structure

Key Metrics to Watch

Financial Metrics

Revenue
20.6M
Net Income
-13.7M
EPS (Diluted)
$-0.33
Free Cash Flow
-10.1M
Total Assets
120.0M
Cash
61.6M

Profitability Ratios

Gross Margin 77.9%
Operating Margin -62.9%
Net Margin -66.3%
ROE -29.8%
ROA -11.4%
FCF Margin -49.1%

Balance Sheet & Liquidity

Current Ratio
4.91x
Quick Ratio
4.04x
Debt/Equity
0.82x
Debt/Assets
61.9%
Interest Coverage
-14.67x
Long-term Debt
37.3M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: 2026-05-06T15:35:51.405194 | Data as of: 2026-03-31 | Powered by Claude AI